
Celiac Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Celiac Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Celiac Disease – Drugs In Development, 2022, provides an overview of the Celiac Disease (Gastrointestinal) pipeline landscape.
Celiac disease is an autoimmune disorder caused by an immune response to wheat protein gluten. Symptoms include weight loss, vomiting, abdominal bloating, abdominal pain and persistent diarrhea. Risk factors include lupus, rheumatoid arthritis, type 1 diabetes, autoimmune liver disease, Sjogren’s syndrome and Turner syndrome. Treatment includes steroids such as betamethasone and prednisolone. Further the treatment regime also involves adhering to strict gluten free diet.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Celiac Disease – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Celiac Disease (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Celiac Disease (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Celiac Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 5, 12, 1, 10 and 9 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.
Celiac Disease (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Celiac Disease – Drugs In Development, 2022, provides an overview of the Celiac Disease (Gastrointestinal) pipeline landscape.
Celiac disease is an autoimmune disorder caused by an immune response to wheat protein gluten. Symptoms include weight loss, vomiting, abdominal bloating, abdominal pain and persistent diarrhea. Risk factors include lupus, rheumatoid arthritis, type 1 diabetes, autoimmune liver disease, Sjogren’s syndrome and Turner syndrome. Treatment includes steroids such as betamethasone and prednisolone. Further the treatment regime also involves adhering to strict gluten free diet.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Celiac Disease – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Celiac Disease (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Celiac Disease (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Celiac Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 5, 12, 1, 10 and 9 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.
Celiac Disease (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Celiac Disease (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Celiac Disease (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Celiac Disease (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Celiac Disease (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Celiac Disease (Gastrointestinal)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Celiac Disease (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Celiac Disease (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
121 Pages
- Introduction
- Global Markets Direct Report Coverage
- Celiac Disease – Overview
- Celiac Disease – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Celiac Disease – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Celiac Disease – Companies Involved in Therapeutics Development
- 9 Meters Biopharma Inc
- Ahead Therapeutics SL
- Allero Therapeutics BV
- Amgen Inc
- Amyra Biotech AG
- Anokion SA
- AnTolRx Inc
- Calypso Biotech SA
- Codexis Inc
- Equillium Inc
- Forte Biosciences Inc
- GSK plc
- ImCyse SA
- Immunic Inc
- ImmunogenX LLC
- ImmunoMolecular Therapeutics LLC
- ImmusanT Inc
- JN Biosciences LLC
- Johnson & Johnson
- Mozart Therapeutics Inc
- Nemysis Ltd
- Parvus Therapeutics Inc
- Pfizer Inc
- Precigen Inc
- Protagonist Therapeutics Inc
- Provention Bio Inc
- SQZ Biotechnologies Co
- Synthetic Biologics Inc
- Takeda Pharmaceutical Co Ltd
- Theravance Biopharma Inc
- Topas Therapeutics GmbH
- Vactech Oy
- Zedira GmbH
- Celiac Disease – Drug Profiles
- AG-017 – Drug Profile
- ALL-001 – Drug Profile
- AMY-01 – Drug Profile
- AMY-02 – Drug Profile
- AT-1715 – Drug Profile
- CALY-002 – Drug Profile
- Celiac Disease – Drug Profile
- Drugs for Celiac Disease – Drug Profile
- E-4002 – Drug Profile
- EQ-102 – Drug Profile
- FB-102 – Drug Profile
- Gluten Management – Drug Profile
- GSK-3915393 – Drug Profile
- HuABC-2 – Drug Profile
- IMU-856 – Drug Profile
- KAN-101 – Drug Profile
- larazotide acetate – Drug Profile
- latiglutenase – Drug Profile
- Monoclonal Antibody to Antagonize IL-2R Beta for Celiac Disease, Oncology and Tropical Spastic Paraparesis – Drug Profile
- Nexvax-2 – Drug Profile
- ordesekimab – Drug Profile
- PRV-101 – Drug Profile
- PTG-100 – Drug Profile
- PVP-001 – Drug Profile
- PVT-301 – Drug Profile
- Small Molecules to Inhibit HLA-DQ2 for Celiac Disease – Drug Profile
- SYN-020 – Drug Profile
- Synthetic Peptide for Celiac Disease – Drug Profile
- TAK-062 – Drug Profile
- TAK-101 – Drug Profile
- TD-5202 – Drug Profile
- tesnatilimab – Drug Profile
- tofacitinib citrate – Drug Profile
- TPM-501 – Drug Profile
- TPM-502 – Drug Profile
- Vaccine for Celiac Disease – Drug Profile
- ZED-1227 – Drug Profile
- ZED-754 – Drug Profile
- Celiac Disease – Dormant Projects
- Celiac Disease – Discontinued Products
- Celiac Disease – Product Development Milestones
- Featured News & Press Releases
- Jun 02, 2022: Immunic provides update on IMU-856
- May 23, 2022: Anokion announces positive data from phase 1 ACeD clinical trial evaluating KAN-101 as a treatment for Celiac Disease presented in a plenary session at DDW 2022
- May 05, 2022: Immunic announces start of patient cohorts in its phase 1 clinical trial of IMU-856 in Celiac Disease
- Mar 28, 2022: Provention Bio announces positive final results from first-in-human study of Coxsackievirus B Vaccine candidate PRV-101
- Mar 21, 2022: 9 Meters Biopharma to present the clinical milestones for larazotide at the Maxim Group 2022 Virtual Growth Conference
- Feb 28, 2022: 9 Meters Biopharma provides clinical update on late-stage pipeline product larazotide for celiac disease
- Jan 06, 2022: Anokion announces progress across pipeline of the drug KAN-101
- Oct 26, 2021: Provention Bio announces positive interim results from first-in-human study of coxsackievirus B vaccine candidate PRV-101
- Sep 13, 2021: SQZ Biotechnologies announces first autoimmune disease indication for Tolerizing Antigen Carrier (TAC) Platform
- Sep 09, 2021: Calypso Biotech announces first patient with celiac disease dosed in anti-interleukin-15 (IL-15) monoclonal antibody CALY-002 phase 1b trial, and extension of series A to €28M
- Jul 01, 2021: Dr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
- May 26, 2021: 9 Meters Biopharma announces publication in journal of clinical investigation describing successful use of larazotide for treating Multisystem Inflammatory Syndrome in Children (MIS-C) resulting from COVID-19 Infection
- May 19, 2021: Nemysis announces grant of first Canadian patent for E-40
- Apr 12, 2021: 9 Meters Biopharma and Celiac Disease Foundation announce collaboration to support clinical trial enrollment in 9 Meters' phase 3 CeDLara study
- Mar 18, 2021: ImmunogenX and Mayo Clinic successfully complete the CeliacShield trial
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development for Celiac Disease, 2022
- Table 2: Number of Products under Development by Companies, 2022
- Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
- Table 4: Number of Products under Development by Universities/Institutes, 2022
- Table 5: Products under Development by Companies, 2022
- Table 6: Products under Development by Companies, 2022 (Contd..1)
- Table 7: Products under Development by Universities/Institutes, 2022
- Table 8: Number of Products by Stage and Target, 2022
- Table 9: Number of Products by Stage and Mechanism of Action, 2022
- Table 10: Number of Products by Stage and Route of Administration, 2022
- Table 11: Number of Products by Stage and Molecule Type, 2022
- Table 12: Celiac Disease – Pipeline by 9 Meters Biopharma Inc, 2022
- Table 13: Celiac Disease – Pipeline by Ahead Therapeutics SL, 2022
- Table 14: Celiac Disease – Pipeline by Allero Therapeutics BV, 2022
- Table 15: Celiac Disease – Pipeline by Amgen Inc, 2022
- Table 16: Celiac Disease – Pipeline by Amyra Biotech AG, 2022
- Table 17: Celiac Disease – Pipeline by Anokion SA, 2022
- Table 18: Celiac Disease – Pipeline by AnTolRx Inc, 2022
- Table 19: Celiac Disease – Pipeline by Calypso Biotech SA, 2022
- Table 20: Celiac Disease – Pipeline by Codexis Inc, 2022
- Table 21: Celiac Disease – Pipeline by Equillium Inc, 2022
- Table 22: Celiac Disease – Pipeline by Forte Biosciences Inc, 2022
- Table 23: Celiac Disease – Pipeline by GSK plc, 2022
- Table 24: Celiac Disease – Pipeline by ImCyse SA, 2022
- Table 25: Celiac Disease – Pipeline by Immunic Inc, 2022
- Table 26: Celiac Disease – Pipeline by ImmunogenX LLC, 2022
- Table 27: Celiac Disease – Pipeline by ImmunoMolecular Therapeutics LLC, 2022
- Table 28: Celiac Disease – Pipeline by ImmusanT Inc, 2022
- Table 29: Celiac Disease – Pipeline by JN Biosciences LLC, 2022
- Table 30: Celiac Disease – Pipeline by Johnson & Johnson, 2022
- Table 31: Celiac Disease – Pipeline by Mozart Therapeutics Inc, 2022
- Table 32: Celiac Disease – Pipeline by Nemysis Ltd, 2022
- Table 33: Celiac Disease – Pipeline by Parvus Therapeutics Inc, 2022
- Table 34: Celiac Disease – Pipeline by Pfizer Inc, 2022
- Table 35: Celiac Disease – Pipeline by Precigen Inc, 2022
- Table 36: Celiac Disease – Pipeline by Protagonist Therapeutics Inc, 2022
- Table 37: Celiac Disease – Pipeline by Provention Bio Inc, 2022
- Table 38: Celiac Disease – Pipeline by SQZ Biotechnologies Co, 2022
- Table 39: Celiac Disease – Pipeline by Synthetic Biologics Inc, 2022
- Table 40: Celiac Disease – Pipeline by Takeda Pharmaceutical Co Ltd, 2022
- Table 41: Celiac Disease – Pipeline by Theravance Biopharma Inc, 2022
- Table 42: Celiac Disease – Pipeline by Topas Therapeutics GmbH, 2022
- Table 43: Celiac Disease – Pipeline by Vactech Oy, 2022
- Table 44: Celiac Disease – Pipeline by Zedira GmbH, 2022
- Table 45: Celiac Disease – Dormant Projects, 2022
- Table 46: Celiac Disease – Dormant Projects, 2022 (Contd..1)
- Table 47: Celiac Disease – Discontinued Products, 2022
- List of Figures
- Figure 1: Number of Products under Development for Celiac Disease, 2022
- Figure 2: Number of Products under Development by Companies, 2022
- Figure 3: Number of Products by Targets, 2022
- Figure 4: Number of Products by Stage and Targets, 2022
- Figure 5: Number of Products by Mechanism of Actions, 2022
- Figure 6: Number of Products by Stage and Mechanism of Actions, 2022
- Figure 7: Number of Products by Routes of Administration, 2022
- Figure 8: Number of Products by Stage and Routes of Administration, 2022
- Figure 9: Number of Products by Top 10 Molecule Types, 2022
- Figure 10: Number of Products by Stage and Top 10 Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.